Corpus ID: 40284111

Preclinical Therapy SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo

  title={Preclinical Therapy SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo},
  author={Patrick Roth and Maria Kissel and Caroline Herrmann and Günter Eisele and Johann Jakob Leban and Michael Weller and Friederike Schmidt},
Purpose: Glioblastomas are among the most lethal neoplasms, with a median survival of <1 year. Modulation of the proteasome function has emerged as a novel approach to cancer pharmacotherapy. Here, we characterized the antitumor properties of SC68896, a novel small molecule proteasome inhibitor. Experimental Design: Different tumor cell lines were tested by crystal violet staining for sensitivity to SC68896, given alone or in combination with death ligands. The molecular mechanisms mediating… 

Figures from this paper


Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.
It is demonstrated that ritonavir, by inhibiting the chymotrypsin-like activity of the proteasome, has cytostatic and cytotoxic effects on glioma cells, and can induce resistances in vitro.
Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
This study is the first to demonstrate that bortezomib, at a clinically relevant dose, did not have any effect on the apoptosis and proliferation of malignant gliomas in vivo.
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
Examining its antiproliferation, proapoptotic effects using three human glioblastoma multiforme cell lines and five primary GBM explants suggests that PS-341 may be an effective therapy for patients with gliomas.
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies by enhancing the antitumor activity of Apo-2L/tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in an intracranial malignant glioma xenograft model in vivo.
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
The results show that proteasome inhibitors induce time- and dose-dependent cell cycle alterations, growth inhibition, and apoptosis in human myeloma cells irrespective of chromosome 13 deletion.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis
TRAIL sensitivity of tumor cell lines is not a reliable predictor for the behavior of primary tumor cells, and the widespread TRAIL resistance in primary glioma cells described here questions the therapeutic clinical benefit of TRAIL as a monotherapeutic agent.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
The present study highlights the important role of DR5 up-regulation in PS-341- induced apoptosis and enhancement of TRAIL-induced apoptosis in human NSCLC cells.
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma
The constitutive expression of natural caspase inhibitors may play a role in the resistance of these cells to apoptotic stimuli that directly target caspases, including radiochemotherapy and immune-mediated tumor cell lysis.
Proteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells
The data indicate that proteasome inhibition induces a p21-independent G2/M arrest and p53-independent apoptosis in human malignant glioma cells.
APO2 ligand: a novel lethal weapon against malignant glioma?
It is reported that human glioma cell lines preferentially express mRNAs for agonistic death receptors DR4 and DR5 rather than the death‐inhibitory decoy receptors DcR1 and Dcr2, which may be a promising approach for selectively targeting apoptosis to human malignant gliomas cells.